Immune responses to HCV and other hepatitis viruses

Immunity

Volumn 40, Issue 1, 2014, Pages 13-24

  Park, Su Hyung ^a   Rehermann, Barbara ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS VACCINE; INTERFERON; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; RIBAVIRIN;

ADAPTIVE IMMUNITY; DELTA AGENT HEPATITIS; HEPATITIS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HEPATITIS E VIRUS; HEPATITIS VIRUS; IMMUNE RESPONSE; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, VIRAL; HEPATITIS C; HEPATITIS VIRUSES; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERONS; VIRAL VACCINES;

EID: 84892449551     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.12.010     Document Type: Review

References (120)

1. Ahlenstiel G., Titerence R.H., Koh C., Edlich B., Feld J.J., Rotman Y., Ghany M.G., Hoofnagle J.H., Liang T.J., Heller T., Rehermann B. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010, 138:325-335. e1-e2.
2. Ahlenstiel G., Edlich B., Hogdal L.J., Rotman Y., Noureddin M., Feld J.J., Holz L.E., Titerence R.H., Liang T.J., Rehermann B. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011, 141:1231-1239. e1-e2.
3. Asabe S., Wieland S.F., Chattopadhyay P.K., Roederer M., Engle R.E., Purcell R.H., Chisari F.V. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J.Virol. 2009, 83:9652-9662.
4. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., Meyer J., Huddart R., Smith K., Townsend R., et al. Novel adenovirus-based vaccines induce broad and sustained Tcell responses to HCV in man. Sci. Transl. Med. 2012, 4:ra1.
5. Bellecave P., Sarasin-Filipowicz M., Donzé O., Kennel A., Gouttenoire J., Meylan E., Terracciano L., Tschopp J., Sarrazin C., Berg T., et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 2010, 51:1127-1136.
6. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., Pircher H., Thimme R. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ Tcells is linked to antigen recognition and Tcell differentiation. PLoS Pathog. 2010, 6:e1000947.
7. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J.Virol. 2001, 75:7059-7066.
8. Bukh J., Thimme R., Meunier J.C., Faulk K., Spangenberg H.C., Chang K.M., Satterfield W., Chisari F.V., Purcell R.H. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J.Virol. 2008, 82:8183-8195.
9. Cheng G., Zhong J., Chisari F.V. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and-independent mechanisms. Proc. Natl. Acad. Sci. USA 2006, 103:8499-8504.
10. Chisari F.V., Isogawa M., Wieland S.F. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 2010, 58:258-266.
11. Dazert E., Neumann-Haefelin C., Bressanelli S., Fitzmaurice K., Kort J., Timm J., McKiernan S., Kelleher D., Gruener N., Tavis J.E., et al. Loss of viral fitness and cross-recognition by CD8+ Tcells limit HCV escape from a protective HLA-B27-restricted human immune response. J.Clin. Invest. 2009, 119:376-386.
12. De Maria A., Fogli M., Mazza S., Basso M., Picciotto A., Costa P., Congia S., Mingari M.C., Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 2007, 37:445-455.
13. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., Eichenlaub D., Pape G.R. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995, 346:1006-1007.
14. Dill M.T., Duong F.H., Vogt J.E., Bibert S., Bochud P.Y., Terracciano L., Papassotiropoulos A., Roth V., Heim M.H. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011, 140:1021-1031.
15. Dreux M., Garaigorta U., Boyd B., Décembre E., Chung J., Whitten-Bauer C., Wieland S., Chisari F.V. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 2012, 12:558-570.
16. Edlich B., Ahlenstiel G., Zabaleta Azpiroz A., Stoltzfus J., Noureddin M., Serti E., Feld J.J., Liang T.J., Rotman Y., Rehermann B. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012, 55:39-48.
17. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., Pezzanera M., Tafi R., Arcuri M., Fattori E., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 2006, 12:190-197.
18. Fonseca J.C. [History of viral hepatitis]. Rev. Soc. Bras. Med. Trop. 2010, 43:322-330.
19. Foy E., Li K., Wang C., Sumpter R., Ikeda M., Lemon S.M., Gale M. Regulation of interferon regulatory factor-3 by the hepatitis Cvirus serine protease. Science 2003, 300:1145-1148.
20. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M.U., Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J.Clin. Invest. 2009, 119:551-564.
21. Fuller M.J., Shoukry N.H., Gushima T., Bowen D.G., Callendret B., Campbell K.J., Hasselschwert D.L., Hughes A.L., Walker C.M. Selection-driven immune escape is not a significant factor in the failure of CD4 Tcell responses in persistent hepatitis C virus infection. Hepatology 2010, 51:378-387.
22. Fuller M.J., Callendret B., Zhu B., Freeman G.J., Hasselschwert D.L., Satterfield W., Sharpe A.H., Dustin L.B., Rice C.M., Grakoui A., et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc. Natl. Acad. Sci. USA 2013, 110:15001-15006.
23. Garaigorta U., Chisari F.V. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009, 6:513-522.
24. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
25. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., Hoffmann R., Schirren C.A., Santantonio T., Pape G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117:933-941.
26. Golden-Mason L., Palmer B., Klarquist J., Mengshol J.A., Castelblanco N., Rosen H.R. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ Tcells associated with reversible immune dysfunction. J.Virol. 2007, 81:9249-9258.
27. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on Tcells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ Tcells. J.Virol. 2009, 83:9122-9130.
28. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., Walker C.M. HCV persistence and immune evasion in the absence of memory Tcell help. Science 2003, 302:659-662.
29. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
30. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., Ford J.C., Oswald K., Shoemaker R., Li Y., Lewis M.S., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
31. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 2013, 13:535-542.
32. Heller T., Werner J.M., Rahman F., Mizukoshi E., Sobao Y., Gordon A.M., Sheets A., Sherker A.H., Kessler E., Bean K.S., et al. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J.Infect. Dis. 2013, 208:1020-1025.
33. Honda M., Sakai A., Yamashita T., Nakamoto Y., Mizukoshi E., Sakai Y., Yamashita T., Nakamura M., Shirasaki T., Horimoto K., et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010, 139:499-509. Hokuriku Liver Study Group.
34. Honegger J.R., Kim S., Price A.A., Kohout J.A., McKnight K.L., Prasad M.R., Lemon S.M., Grakoui A., Walker C.M. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat. Med. 2013, 19:1529-1533.
35. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49(Suppl):S156-S165.
36. Hoofnagle J.H., Nelson K.E., Purcell R.H. Hepatitis E. N.Engl. J. Med. 2012, 367:1237-1244.
37. Horner S.M., Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 2013, 19:879-888.
38. Kared H., Fabre T., Bédard N., Bruneau J., Shoukry N.H. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog. 2013, 9:e1003422.
39. Kasprowicz V., Schulze Zur Wiesch J., Kuntzen T., Nolan B.E., Longworth S., Berical A., Blum J., McMahon C., Reyor L.L., Elias N., et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ Tcells during acute HCV infection, irrespective of clinical outcome. J.Virol. 2008, 82:3154-3160.
40. Kong L., Giang E., Nieusma T., Kadam R.U., Cogburn K.E., Hua Y., Dai X., Stanfield R.L., Burton D.R., Ward A.B., et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013, 342:1090-1094.
41. Kroy D.C., Ciuffreda D., Cooperider J.H., Tomlinson M., Hauck G.D., Aneja J., Berger C., Wolski D., Carrington M., Wherry E.J., et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 2013, Published online October 19, 2013. 10.1053/j.gastro.2013.10.022.
42. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., Ray S.C., Thomas D.L. Cross-genotype immunity to hepatitis C virus. J.Virol. 2004, 78:1575-1581.
43. Lanford R.E., Feng Z., Chavez D., Guerra B., Brasky K.M., Zhou Y., Yamane D., Perelson A.S., Walker C.M., Lemon S.M. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc. Natl. Acad. Sci. USA 2011, 108:11223-11228.
44. Langhans B., Kupfer B., Braunschweiger I., Arndt S., Schulte W., Nischalke H.D., Nattermann J., Oldenburg J., Sauerbruch T., Spengler U. Interferon-lambda serum levels in hepatitis C. J.Hepatol. 2011, 54:859-865.
45. Lau D.T., Fish P.M., Sinha M., Owen D.M., Lemon S.M., Gale M. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology 2008, 47:799-809.
46. Lau D.T., Negash A., Chen J., Crochet N., Sinha M., Zhang Y., Guedj J., Holder S., Saito T., Lemon S.M., et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013, 144:402-413. e12.
47. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J.Exp. Med. 2000, 191:1499-1512.
48. Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J.Hepatol. 2009, 51:581-592.
49. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. USA 2005, 102:2992-2997.
50. Li K., Li N.L., Wei D., Pfeffer S.R., Fan M., Pfeffer L.M. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55:666-675.
51. Liang T.J. Current progress in development of hepatitis C virus vaccines. Nat. Med. 2013, 19:869-878.
52. Liang Y., Shilagard T., Xiao S.Y., Snyder N., Lau D., Cicalese L., Weiss H., Vargas G., Lemon S.M. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology 2009, 137:1448-1458.
53. Lindenbach B.D., Rice C.M. The ins and outs of hepatitis C virus entry and assembly. Nat. Rev. Microbiol. 2013, 11:688-700.
54. Lindenbach B.D., Meuleman P., Ploss A., Vanwolleghem T., Syder A.J., McKeating J.A., Lanford R.E., Feinstone S.M., Major M.E., Leroux-Roels G., Rice C.M. Cell culture-grown hepatitis C virus is infectious invivo and can be recultured invitro. Proc. Natl. Acad. Sci. USA 2006, 103:3805-3809.
55. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2004, 101:10149-10154.
56. Lohmann V., Bartenschlager R. On the history of hepatitis C virus cell culture systems. J.Med. Chem. 2013, Published online October 28, 2013. 10.1021/jm401401n.
57. Loo Y.M., Owen D.M., Li K., Erickson A.K., Johnson C.L., Fish P.M., Carney D.S., Wang T., Ishida H., Yoneyama M., et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2006, 103:6001-6006.
58. McFarland A.P., Horner S.M., Jarret A., Joslyn R.C., Bindewald E., Shapiro B.A., Delker D.A., Hagedorn C.H., Carrington M., Gale M., Savan R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 2013, 15:72-79.
59. McMahan R.H., Golden-Mason L., Nishimura M.I., McMahon B.J., Kemper M., Allen T.M., Gretch D.R., Rosen H.R. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed invitro cytotoxicity. J.Clin. Invest. 2010, 120:4546-4557.
60. Mehta S.H., Cox A., Hoover D.R., Wang X.H., Mao Q., Ray S., Strathdee S.A., Vlahov D., Thomas D.L. Protection against persistence of hepatitis C. Lancet 2002, 359:1478-1483.
61. Metz P., Reuter A., Bender S., Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. J.Hepatol. 2013, 59:1331-1341.
62. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., Ferrari C. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J.Clin. Invest. 1996, 98:706-714.
63. Miyagi T., Gil M.P., Wang X., Louten J., Chu W.M., Biron C.A. High basal STAT4 balanced by STAT1 induction to control type 1 interferon effects in natural killer cells. J.Exp. Med. 2007, 204:2383-2396.
64. Miyagi T., Takehara T., Nishio K., Shimizu S., Kohga K., Li W., Tatsumi T., Hiramatsu N., Kanto T., Hayashi N. Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection. J.Hepatol. 2010, 53:424-430.
65. Mizukoshi E., Eisenbach C., Edlin B.R., Newton K.P., Raghuraman S., Weiler-Normann C., Tobler L.H., Busch M.P., Carrington M., McKeating J.A., et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J.Infect. Dis. 2008, 198:203-212.
66. Nakamoto N., Cho H., Shaked A., Olthoff K., Valiga M.E., Kaminski M., Gostick E., Price D.A., Freeman G.J., Wherry E.J., Chang K.M. Synergistic reversal of intrahepatic HCV-specific CD8 Tcell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009, 5:e1000313.
67. Nascimbeni M., Mizukoshi E., Bosmann M., Major M.E., Mihalik K., Rice C.M., Feinstone S.M., Rehermann B. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J.Virol. 2003, 77:4781-4793.
68. Negash A.A., Ramos H.J., Crochet N., Lau D.T., Doehle B., Papic N., Delker D.A., Jo J., Bertoletti A., Hagedorn C.H., Gale M. IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog. 2013, 9:e1003330.
69. Oliviero B., Varchetta S., Paudice E., Michelone G., Zaramella M., Mavilio D., De Filippi F., Bruno S., Mondelli M.U. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009, 137:1151-1160. e1-e7.
70. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., Thomas D.L., Cox A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
71. Osterlund P.I., Pietilä T.E., Veckman V., Kotenko S.V., Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J.Immunol. 2007, 179:3434-3442.
72. Park H., Serti E., Eke O., Muchmore B., Prokunina-Olsson L., Capone S., Folgori A., Rehermann B. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 2012, 56:2060-2070.
73. Park S.H., Shin E.C., Capone S., Caggiari L., De Re V., Nicosia A., Folgori A., Rehermann B. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis Cvirus. Gastroenterology 2012, 143:1048-1060. e4.
74. Park S.H., Veerapu N.S., Shin E.C., Biancotto A., McCoy J.P., Capone S., Folgori A., Rehermann B. Subinfectious hepatitis C virus exposures suppress Tcell responses against subsequent acute infection. Nat. Med. 2013, 19:1638-1642.
75. Pestka J.M., Zeisel M.B., Bläser E., Schürmann P., Bartosch B., Cosset F.L., Patel A.H., Meisel H., Baumert J., Viazov S., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 2007, 104:6025-6030.
76. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., Hergott D., Porter-Gill P., Mumy A., Kohaar I., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 isassociated with impaired clearance of hepatitis C virus. Nat. Genet. 2013, 45:164-171.
77. Qu L., Lemon S.M. Hepatitis A and hepatitis C viruses: divergent infection outcomes marked by similarities in induction and evasion of interferon responses. Semin. Liver Dis. 2010, 30:319-332.
78. Qu L., Feng Z., Yamane D., Liang Y., Lanford R.E., Li K., Lemon S.M. Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog. 2011, 7:e1002169.
79. Radziewicz H., Ibegbu C.C., Fernandez M.L., Workowski K.A., Obideen K., Wehbi M., Hanson H.L., Steinberg J.P., Masopust D., Wherry E.J., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J.Virol. 2007, 81:2545-2553.
80. Rahman F., Heller T., Sobao Y., Mizukoshi E., Nascimbeni M., Alter H., Herrine S., Hoofnagle J., Liang T.J., Rehermann B. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004, 40:87-97.
81. Ramakrishnaiah V., Thumann C., Fofana I., Habersetzer F., Pan Q., de Ruiter P.E., Willemsen R., Demmers J.A., Stalin Raj V., Jenster G., et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc. Natl. Acad. Sci. USA 2013, 110:13109-13113.
82. Raziorrouh B., Ulsenheimer A., Schraut W., Heeg M., Kurktschiev P., Zachoval R., Jung M.C., Thimme R., Neumann-Haefelin C., Horster S., et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ Tcells in patients with chronic infection. Gastroenterology 2011, 141:1422-1431. e1-e6.
83. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J.Clin. Invest. 2009, 119:1745-1754.
84. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of Tcells and NK cells. Nat. Med. 2013, 19:859-868.
85. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996, 2:1104-1108.
86. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W., Heim M.H. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. USA 2008, 105:7034-7039.
87. Scheel T.K., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013, 19:837-849.
88. Schlaphoff V., Lunemann S., Suneetha P.V., Jaroszewicz J., Grabowski J., Dietz J., Helfritz F., Bektas H., Sarrazin C., Manns M.P., et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ Tcells. PLoS Pathog. 2011, 7:e1002045.
89. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
90. Semmo N., Day C.L., Ward S.M., Lucas M., Harcourt G., Loughry A., Klenerman P. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005, 41:1019-1028.
91. Shiina M., Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 2008, 47:385-395.
92. Shin E.C., Seifert U., Kato T., Rice C.M., Feinstone S.M., Kloetzel P.M., Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J.Clin. Invest. 2006, 116:3006-3014.
93. Shin E.C., Park S.H., Nascimbeni M., Major M., Caggiari L., de Re V., Feinstone S.M., Rice C.M., Rehermann B. The frequency of CD127(+) hepatitis C virus (HCV)-specific Tcells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J.Virol. 2013, 87:4772-4777.
94. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., Walker C.M. Memory CD8+ Tcells are required for protection from persistent hepatitis C virus infection. J.Exp. Med. 2003, 197:1645-1655.
95. Smyk-Pearson S., Tester I.A., Klarquist J., Palmer B.E., Pawlotsky J.M., Golden-Mason L., Rosen H.R. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J.Virol. 2008, 82:1827-1837.
96. Su A.I., Pezacki J.P., Wodicka L., Brideau A.D., Supekova L., Thimme R., Wieland S., Bukh J., Purcell R.H., Schultz P.G., Chisari F.V. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 2002, 99:15669-15674.
97. Takahashi K., Asabe S., Wieland S., Garaigorta U., Gastaminza P., Isogawa M., Chisari F.V. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc. Natl. Acad. Sci. USA 2010, 107:7431-7436.
98. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J.L., Manns M.P., Rehermann B. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 2000, 6:578-582.
99. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
100. Taylor J.M. Virology of hepatitis D virus. Semin. Liver Dis. 2012, 32:195-200.
101. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., Schreiber R.D., de la Torre J.C., Oldstone M.B. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
102. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J.Exp. Med. 2001, 194:1395-1406.
103. Thimme R., Bukh J., Spangenberg H.C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R.H., Chisari F.V. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. USA 2002, 99:15661-15668.
104. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
105. Thomas E., Gonzalez V.D., Li Q., Modi A.A., Chen W., Noureddin M., Rotman Y., Liang T.J. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012, 142:978-988.
106. Thurairajah P.H., Hegazy D., Chokshi S., Shaw S., Demaine A., Kaminski E.R., Naoumov N.V., Cramp M.E. Hepatitis C virus (HCV)-specific Tcell responses in injection drug users with apparent resistance to HCV infection. J.Infect. Dis. 2008, 198:1749-1755.
107. Timm J., Lauer G.M., Kavanagh D.G., Sheridan I., Kim A.Y., Lucas M., Pillay T., Ouchi K., Reyor L.L., Schulze zur Wiesch J., et al. CD8 epitope escape and reversion in acute HCV infection. J.Exp. Med. 2004, 200:1593-1604.
108. Timpe J.M., Stamataki Z., Jennings A., Hu K., Farquhar M.J., Harris H.J., Schwarz A., Desombere I., Roels G.L., Balfe P., McKeating J.A. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008, 47:17-24.
109. Urban T.J., Thompson A.J., Bradrick S.S., Fellay J., Schuppan D., Cronin K.D., Hong L., McKenzie A., Patel K., Shianna K.V., et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010, 52:1888-1896.
110. Urbani S., Amadei B., Fisicaro P., Tola D., Orlandini A., Sacchelli L., Mori C., Missale G., Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 2006, 44:126-139.
111. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection invivo. Gastroenterology 2007, 132:667-678.
112. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Kräusslich H.G., Mizokami M., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
113. Wang N., Liang Y., Devaraj S., Wang J., Lemon S.M., Li K. Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J.Virol. 2009, 83:9824-9834.
114. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 2004, 101:6669-6674.
115. Wieland S., Makowska Z., Campana B., Calabrese D., Dill M.T., Chung J., Chisari F.V., Heim M.H. Simultaneous detection of hepatitis Cvirus and interferon stimulated gene expression in infected human liver. Hepatology 2013, Published online October 3, 2013. 10.1002/hep.26770.
116. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., Aronow B.J., Karp C.L., Brooks D.G. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
117. Yang Y., Liang Y., Qu L., Chen Z., Yi M., Li K., Lemon S.M. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl. Acad. Sci. USA 2007, 104:7253-7258.
118. Zhang S., Kodys K., Li K., Szabo G. Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology 2013, 144:414-425. e7.
119. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection invitro. Proc. Natl. Acad. Sci. USA 2005, 102:9294-9299.
120. Zhou Y., Callendret B., Xu D., Brasky K.M., Feng Z., Hensley L.L., Guedj J., Perelson A.S., Lemon S.M., Lanford R.E., Walker C.M. Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J.Exp. Med. 2012, 209:1481-1492.